2 compelling stocks for the value investor

Vision Eye Institute Limited (ASX:VEI) and SDI Limited (ASX:SDI) are attracting the interest of value investors.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

"We don't get paid for activity, just for being right. As to how long we'll wait, we'll wait indefinitely." – Warren Buffett

It's not every day that you find a share worth buying. But value investors, unlike technical traders, (should) spend a lot of time trying to value companies so they can pounce on value opportunities when they arrive. Here are two stocks that currently offer decent value and may well prove to be an excellent opportunity if they become cheaper or if results are positive. Mr Market is not expecting too much of these two stocks…

The first is Vision Eye Institute Ltd (ASX: VEI) the owner of various ophthalmology practices. The company's main services are consultations, laser eye surgery and surgical services (for example, treatment of cataracts and macular degeneration). Macular degeneration, for example, is more prevalent in an older population that is more overweight than ever.

More generally the Australian population is ageing and we are facing an obesity epidemic, so I'm making the prediction that demand for ophthalmological surgical services will only increase in the years to come. However, the problem with this is that the eye doctors already hold too much bargaining power, and can profit at the expense of shareholders by demanding ever better terms of engagement.

This problem could be diminished if Vision Eye Institute were taken over by Primary Healthcare Limited (ASX: PRY), because Primary Healthcare also manages general medical practices and diagnostic practices. Therefore, Primary Healthcare could add more value to ophthalmologists by utilising its existing network to grow referrals, and it could also use its existing managerial expertise to reduce costs. In my view, Vision Eye Institute is worth more to Primary Healthcare than it is as a standalone business, but even as a standalone business, it looks cheap at current prices of under 80c, assuming its second half results show some incremental improvements.

A little over a week ago I wrote that Vision Eye Institute is undervalued at 70c based on an assumption of no growth in the second half of 2014. Furthermore, in my view the company would be worth significantly more than $1 per share to Primary Healthcare, which already owns over 20%. The recent share price plunge – resulting from the fact that the founder is suing the company – was probably a buying opportunity. It may pay to keep an eye out for the results: if gross margins have actually improved, I would be increasing my valuation accordingly.

An even more attractive option might be SDI Limited (ASX: SDI), a company that manufactures and sells dental equipment and material such as amalgams (for fillings) and tooth whitening systems. The company exports about 90% of its products, and has predicted it will earn $5.7 – $6.2 million in FY 2014. Although this equates to a likely 2014 P/E ratio of slightly above 12, there seems to be a decent likelihood that profits will continue to grow into FY 2015.

The company's founder is chairman Jeffery Cheetham. The Cheethams effectively control the company, and various family members occupy key roles. Whether this is a good thing or a bad thing depends entirely on the way the controlling family treat retail shareholders. There is a huge difference for example, between the way that Murdoch runs "his" company and the laudable leadership of the Moufarrige family at Servcorp Limited (ASX: SRV).

Although the share price is up over 10% since I first covered the company, an increased dividend plus profit of $6.1 million or above would suggest that SDI is still a good value opportunity, even at 60c per share.

However, SDI Limited does not have a great history of paying huge dividends and the company has not generated strong returns for shareholders in the last decade. Nonetheless, I think profits will grow over the next couple of years because new products should boost sales, the company benefits from a weaker Australian dollar, and the price of silver (a major input cost for the company) has come down. It also helps the buy thesis that directors were buying shares on market quite recently.

Motley Fool contributor Claude Walker (@claudedwalker) owns shares in SDI Limited.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »